Bio Tech & Pharma Notable Advancements in Targeted Radioimmunotherapy with B7-H3 Antibody (BetaBart)By Alexander LeeOctober 6, 20240 Amgen’s Executive Vice President of Research and Development, Dr. Jay Bradner, emphasized the significance of TEPEZZA’s approval in Asia as…
Bio Tech & Pharma Appendix 4E and Preliminary Final Report for the Fiscal Year Ending June 30, 2024By Alexander LeeAugust 29, 20240 Amgen has announced the approval of a new oral treatment option for children and adolescents with moderate to severe plaque…
Bio Tech & Pharma RAD Expands Ownership Stake in Radiopharm Ventures to 75%By Alexander LeeAugust 25, 20240 Radiopharm Ventures has announced that RAD has increased its ownership stake in the company to 75%. This move demonstrates RAD’s…
